Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Commentary

Informed consent: time for more transparency

Yusuf Yazici1* and Hasan Yazici2

Author affiliations

1 New York University School of Medicine, NYU Hospital for Joint Diseases, 246 East 20th Street, New York, NY 10003, USA

2 University of Istanbul, Cerrahpasa School of Medicine, Fatih, Istanbul, 34098, Turkey

For all author emails, please log on.

Citation and License

Arthritis Research & Therapy 2010, 12:121  doi:10.1186/ar3004

Published: 3 June 2010

Abstract

Informed consent is not only for documenting a patient's acceptance of enrolling in a clinical trial. It currently is the patient's and, we propose, should also be the public's main source of information regarding the reasons for the planned study, what is known in the field about the proposed trial, and what to expect as far as efficacy and harm. Informed consent is not currently part of the clinical trial registries. For purposes of full disclosure to the patients and the public, the informed consent should be part of the required documents for such registries.